Company Performance Metrics
Douglas Abrams: CFOPast Role: IAN Group, co-Deputy Chairman
Meticuly is a medical device company that specializes in AI-driven design and 3D-printed patient-specific titanium implants for cranial, maxillofacial, and orthopedic surgeries. Founded in 2017, the company leverages in-house developed AI engines and precision manufacturing to create custom implants tailored to individual patients, allowing
Meticuly to achieve the fastest lead time in the industry.
The company has served over 1,700 cases across more than 160 hospitals in Southeast Asia, the Middle East, and the UK. As the SEA market leader, Meticuly has expanded the flagship product families to the U.S. with two 510(k) clearances in 2022 and 2024. Meticuly holds 71 intellectual properties in its portfolio, globally applied across relevant markets. This achievement reflects its recognition as the 2024 WIPO Global Award winner from the World Intellectual Property Organization for innovation and intellectual property excellence, marking Meticuly as the first Thai startup to receive this honor.
Meticuly complies with ISO 13485 and Medical Device Single Audit Program standards for quality management, reflecting its focus on enhancing clinical outcomes and patient care. Leveraging this foundational knowledge, Meticuly is now shaping the future of medical implants by deploying robust and scalable 3D printing at the point of care, marking a world-first milestone.
